These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9155158)

  • 1. [Metallothionein].
    Naganuma A
    Nihon Rinsho; 1997 May; 55(5):1091-5. PubMed ID: 9155158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice.
    Okazaki Y; Miura N; Satoh M; Imura N; Naganuma A
    Biochem Biophys Res Commun; 1998 Apr; 245(3):815-8. PubMed ID: 9588197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of metallothionein in cancer chemotherapy].
    Naganuma A; Imura N
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metallothionein as a resistance factor for antitumor drugs].
    Imura N; Naganuma A; Satoh M
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):599-604. PubMed ID: 2705789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs.
    Lazo JS; Basu A
    Semin Cancer Biol; 1991 Aug; 2(4):267-71. PubMed ID: 1912530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
    Tikoo K; Ali IY; Gupta J; Gupta C
    Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
    Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
    Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metallothionein and cancer].
    Li X; Ru B
    Wei Sheng Yan Jiu; 1999 May; 28(3):185-7. PubMed ID: 12712730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallothionein null cells have increased sensitivity to anticancer drugs.
    Kondo Y; Woo ES; Michalska AE; Choo KH; Lazo JS
    Cancer Res; 1995 May; 55(10):2021-3. PubMed ID: 7743495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential transactivation of human metallothionein-IIa in cisplatin-resistant and -sensitive cells.
    Yang YY; Robbins PD; Lazo JS
    Oncol Res; 1998; 10(2):85-98. PubMed ID: 9666516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
    Morton KA; Jones BJ; Sohn MH; Datz FL; Lynch RE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):697-702. PubMed ID: 8246143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
    Tomida A; Tsuruo T
    Anticancer Drug Des; 1999 Apr; 14(2):169-77. PubMed ID: 10405643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
    Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
    Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of the expression of mouse metallothionein-I gene in human HeLa cell line on drug resistance].
    Li X; Lü W; Yin S; Li L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):199-201. PubMed ID: 12520915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effect of metallothionein against toxicity of anticancer drugs].
    Naganuma A; Imura N
    Tanpakushitsu Kakusan Koso; 1987 Jul; 32(8):1031-40. PubMed ID: 3313521
    [No Abstract]   [Full Text] [Related]  

  • 17. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.
    Satoh M; Cherian MG; Imura N; Shimizu H
    Cancer Res; 1994 Oct; 54(20):5255-7. PubMed ID: 7923149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metallothioneins and resistance to cisplatin and radiation in prostate cancer.
    Smith DJ; Jaggi M; Zhang W; Galich A; Du C; Sterrett SP; Smith LM; Balaji KC
    Urology; 2006 Jun; 67(6):1341-7. PubMed ID: 16765200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells.
    Laurencot CM; Kennedy KA
    Oncol Res; 1995; 7(7-8):371-9. PubMed ID: 8747600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.